A novel mode of action of YC-1 in HIF inhibition: Stimulation of FIH-dependent p300 dissociation from HIF-1α

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3729-3738

  Shan, Hua Li ^a   Dong, Hoon Shin ^a   Chun, Yang Sook ^a   Myung, Kyu Lee ^b   Kim, Myung Suk ^a   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN FACTOR INHIBITING HIF; PROTEIN P300; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION;

AMINO ACIDS, DICARBOXYLIC; CELL LINE, TUMOR; ENZYME ACTIVATORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; MODELS, BIOLOGICAL; P300-CBP TRANSCRIPTION FACTORS; PLASMIDS; PROTEIN BIOSYNTHESIS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 57749106966     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0074     Document Type: Article

References (42)

1. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17:71-7.
2. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
3. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 1998;92:2260-8.
4. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271:17771-8.
5. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
6. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-61.
7. Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett 2004;207:1-7.
8. Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-54.
9. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
10. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007;26:341-52.
11. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
12. Shin DH, Kim JH, Jung YJ, et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007;255:107-16.
13. Song SJ, Chung H, Yu HG. Inhibitory effect of YC-1, 3-(5′- hydroxymethyl-2′-furyl)-1-benzylindazole, on experimental choroidal neovascularization in rat. Ophthalmic Res 2007;40:35-40.
14. Kim HL, Yeo EJ, Chun YS, Park JW. A domain responsible for HIF-1α degradation by YC-1,a novel anticancer agent. Int J Oncol 2006;29:255-60.
15. Lau CK, Yang ZF, Lam CT, Tam KH, Poon RT, Fan ST. Suppression of hypoxia inducible factor-1α (HIF-1α) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 2006;348:1443-8.
16. Sun HL, Liu YN, Huang YT, et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene 2007;26:3941-51.
17. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6:33-43.
18. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006;57:33-47.
19. Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1α C-terminal activation domain. Mol Cell Biol 2006;26:5895-907.
20. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008;111:3131-6.
21. Shin DH, Li SH, Chun YS, Huang LE, Kim MS, Park JW. CITED2 mediates the paradoxical responses of HIF-1α to proteasome inhibition. Oncogene 2007;27:1939-44.
22. Yeo EJ, Ryu JH, Cho YS, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 2006;107:916-23.
23. Lee SH, Moon JH, Cho EA, Ryu SE, Lee MK. Monoclonal antibody-based screening assay for factor inhibiting hypoxia-inducible factor inhibitors. J Biomol Screen 2008;13:494-503.
24. Gu J, Milligan J, Huang LE. Molecular mechanism of hypoxia-inducible factor 1α-p300 interaction. A leucine-rich interface regulated by a single cysteine. J Biol Chem 2001;276:3550-4.
25. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:2675-86.
26. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002;277:26351-5.
27. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71.
28. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004;279:9899-904.
29. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol 2004;68:1145-55.
30. Freedman SJ, Sun ZY, Kung AL, France DS, Wagner G, Eck MJ. Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2. Nat Struct Biol 2003;10:504-12.
31. Cockman ME, Lancaster DE, Stolze IP, et al. Posttranslational hydroxylation of ankyrin repeats in IκB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase,factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A 2006;103:14767-72.
32. Coleman ML, McDonough MA, Hewits on KS, et al. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem 2007;282:24027-38.
33. Zheng X, Linke S, Dias JM, et al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci U S A 2008;105:3368-73.
34. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84:4226-33.
35. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 1998;54:962-7.
36. Yeo EJ, Ryu JH, Chun YS, et al. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 2006;66:6345-52.
37. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007;67:563-72.
38. Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004;36:530-9.
39. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359-69.
40. Sánchez-Puig N, Veprintsev DB, Fersht AR. Binding of natively unfolded HIF-1α ODD domain to p53. Mol Cell 2005;17:11-21.
41. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007;12:108-13.
42. Kaidi A, Williams AC, Paraskeva C. Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007;9:210-7.